United Therapeutics Corporation (UTHR)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
Tyvaso Revenue	1.83B	1.62B	Log In	Log In	Log In	Upgrade
Remodulin Revenue	533.30M	538.10M	Log In	Log In	Log In	Upgrade
Orenitram Revenue	483.50M	434.30M	Log In	Log In	Log In	Upgrade
Unituxin Revenue	232.00M	238.70M	Log In	Log In	Log In	Upgrade
Adcirca Revenue	26.90M	23.80M	Log In	Log In	Log In	Upgrade
Total Product Sales Revenue	3.11B	2.86B	Log In	Log In	Log In	Upgrade
Revenue (Other)	22.90M	22.10M	Log In	Log In	Log In	Upgrade
Revenue (Total)	3.13B	2.88B	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
United States Revenue	2.99B	2.74B	Log In	Log In	Log In	Upgrade
Rest-of-World Revenue	138.50M	137.70M	Log In	Log In	Log In	Upgrade
Revenue (Total)	3.13B	2.88B	Log In	Log In	Log In	Upgrade

Gross Profit

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
Tyvaso Gross Profit	1.61B	1.44B	Log In	Log In	Log In	Upgrade
Remodulin Gross Profit	478.70M	490.70M	Log In	Log In	Log In	Upgrade
Orenitram Gross Profit	456.00M	405.90M	Log In	Log In	Log In	Upgrade
Unituxin Gross Profit	218.20M	224.30M	Log In	Log In	Log In	Upgrade
Adcirca Gross Profit	15.40M	13.70M	Log In	Log In	Log In	Upgrade
Total Product Sales Gross Profit	2.78B	2.57B	Log In	Log In	Log In	Upgrade
Gross Profit (Other)	-9.90M	-4.80M	Log In	Log In	Log In	Upgrade
Gross Profit (Total)	2.77B	2.57B	Log In	Log In	Log In	Upgrade

Updated Oct 29, 2025. Data Source: Fiscal.ai.